ReviewDiseases (Basel, Switzerland)2023
Primary Bone Lymphoma: A Review of the Literature with Emphasis on Histopathology and Histogenesis.
Review in Diseases (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- Primary bone lymphoma: a radiologic-pathologic series of 72 cases uncovering the diagnostic complexity of a rare and heterogeneous entity.Skeletal radiology · 2026Article
- Clinical Characteristics and Prognostic Factors of Primary Bone Diffuse Large B-Cell Lymphoma: A Retrospective Study.Cancer medicine · 2026Article
- Pathological fracture of primary lymphoma of bone: A case report on diagnosis and novel surgical management.Oncology letters · 2026Article
- Article
- Knee-Deep in Bias: When the Low-Probability Diagnosis of Double-Expressor Lymphoma Wins.Cureus · 2026Article
- Primary diffuse large B-cell lymphoma of the rectus abdominis muscle: a presumed primary case report and literature review.Frontiers in oncology · 2026Article
- Deceptive initial presentation of systemic DLBCL with CNS progression following Oligometabolic PET/CT: case report.Frontiers in oncology · 2026Article
- Bone lesions of the tibia: Multimodal iconographic review and diagnostic algorithms, Part 2: Metaphyseal and epiphyseal lesions.European journal of radiology open · 2025Review
- Epidemiology and survival of patients with primary lymphoma of bone: a large retrospective cohort study.Annals of hematology · 2025Article
- Rare Case of Primary Bone Lymphoma.Cureus · 2025Article
- Multiple primary bone lymphoma in children: a case description.Quantitative imaging in medicine and surgery · 2025Article
- Spinal lesions: a comprehensive radiologic overview.Frontiers in radiology · 2025Review
- Delayed diagnosis of a primary diffuse large B-cell lymphoma of the humeral head, presenting as pathological fracture: a case report and review of the literature.JSES reviews, reports, and techniques · 2024Article
- Conditional survival of patients with primary bone lymphoma of the spine: how survival changes after initial diagnosis.Frontiers in oncology · 2024Article
- Case report: When infection lurks behind malignancy: a unique case of primary bone lymphoma mimicking infectious process in the spine.Frontiers in nuclear medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary bone lymphoma (PBL) is a rare neoplasm of malignant lymphoid cells presenting with one or more bone lesions without nodal or other extranodal involvement. It accounts for approximately 1% of all lymphomas and 7% of malignant primary bone tumors. Diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) represents the predominant histological type and constitutes over 80% of all cases. PBL may occur at all ages with a typical diagnosis age of 45-60 years and a slight male predominance. Local bone pain, soft tissue edema, palpable mass and pathological fracture are the most common clinical features. Diagnosis of the disease, which is frequently delayed due to its non-specific clinical presentation, is based on the combination of clinical examination and imaging studies and confirmed by combined histopathological and immunohistochemical examination. PBL can develop in any part of the skeleton, although it occurs most commonly in the femur, humerus, tibia, spine and pelvis. The imaging appearance of PBL is highly variable and unspecific. In terms of the cell-of-origin, most cases of primary bone DLBCL (PB-DLBCL), NOS belong to the germinal center B-cell-like subtype and specifically originate from germinal center centrocytes. PB-DLBCL, NOS has been considered a distinct clinical entity based on its particular prognosis, histogenesis, gene expression and mutational profile and miRNA signature. PBL carries a favorable prognosis, especially when treated with combined chemoradiotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.